Free Trial
OTCMKTS:NVZMY

Novozymes A/S (NVZMY) Stock Price, News & Analysis

Novozymes A/S logo
$61.16 +2.44 (+4.16%)
As of 04/3/2025 03:59 PM Eastern

About Novozymes A/S Stock (OTCMKTS:NVZMY)

Key Stats

Today's Range
$59.59
$62.40
50-Day Range
$55.74
$62.57
52-Week Range
$52.96
$72.50
Volume
31,073 shs
Average Volume
19,484 shs
Market Capitalization
$28.64 billion
P/E Ratio
38.71
Dividend Yield
2.45%
Price Target
N/A
Consensus Rating
Buy

Company Overview

Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services. In addition, the company provides dishwashing, softener, microbial and medical cleaning services. Further, it provides corn, cotton, forages, peanuts, pulses, soybeans, wheat, small grains, bioyield, and biocontrol solutions; warm water species, recirculating aquaculture system; animal health and nutrition solutions; fiber modification, bleach boosting, deposit control, and starch modification solutions. Additionally, the company provides carbon capture, leather and textiles solutions; enzyme solutions, including corn and wheat separation, liquefaction, saccharification, filtration, isomerization, maltose, and specialties solutions; warm water species and recirculating aquaculture system solutions; human health solutions, comprising brain, oral, protective and immune, and gastrointestinal health solutions; ethanol, biodiesel, renewable diesel, education, wastewater, and sewage sludge, and renewable diesel solutions; agriculture and industry, biogas food waste, food waste, biocatalysis, cell culture, diagnostics, enzyme, and biogas solutions. Furthermore, it provides lipases, proteases, oxidoreductases, and carbohydrases. Novozymes A/S was founded in 1925 and is based in Bagsvaerd, Denmark.

Remove Ads

Novozymes A/S Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
35th Percentile Overall Score

NVZMY MarketRank™: 

Novozymes A/S scored higher than 35% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Novozymes A/S are expected to grow by 17.58% in the coming year, from $1.82 to $2.14 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Novozymes A/S is 38.71, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 21.15.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Novozymes A/S is 38.71, which means that it is trading at a less expensive P/E ratio than the Basic Materials sector average P/E ratio of about 71.64.

  • Price to Earnings Growth Ratio

    Novozymes A/S has a PEG Ratio of 3.87. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Novozymes A/S has a P/B Ratio of 13.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Novozymes A/S's valuation and earnings.
  • Percentage of Shares Shorted

    0.00% of the float of Novozymes A/S has been sold short.
  • Short Interest Ratio / Days to Cover

    Novozymes A/S has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Novozymes A/S has recently increased by 1,600.00%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Novozymes A/S has a dividend yield of 0.60%, which is in the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Novozymes A/S does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Novozymes A/S is 94.94%. Payout ratios above 75% are not desirable because they may not be sustainable.

  • Dividend Sustainability

    Based on earnings estimates, Novozymes A/S will have a dividend payout ratio of 70.09% next year. This indicates that Novozymes A/S will be able to sustain or increase its dividend.

  • Read more about Novozymes A/S's dividend.
  • Percentage of Shares Shorted

    0.00% of the float of Novozymes A/S has been sold short.
  • Short Interest Ratio / Days to Cover

    Novozymes A/S has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Novozymes A/S has recently increased by 1,600.00%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Novozymes A/S has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Basic Materials companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Novozymes A/S this week, compared to 0 articles on an average week.
Receive NVZMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novozymes A/S and its competitors with MarketBeat's FREE daily newsletter.

NVZMY Stock News Headlines

Novonesis price target lowered to DKK 490 from DKK 500 at Barclays
Invitation to the Annual General Meeting
Trump Orders 'National Digital Asset Stockpile'
‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more traction
Novonesis (Novozymes) B ADR
Novonesis: Still Too Expensive
Novonesis added to European Conviction List at Goldman Sachs
Novonesis Reports Strong Q3 Growth in 2024
See More Headlines

NVZMY Stock Analysis - Frequently Asked Questions

Novozymes A/S's stock was trading at $56.5399 at the beginning of the year. Since then, NVZMY stock has increased by 8.2% and is now trading at $61.16.
View the best growth stocks for 2025 here
.

Novozymes A/S (OTCMKTS:NVZMY) posted its quarterly earnings results on Wednesday, January, 31st. The biotechnology company reported $0.36 earnings per share for the quarter, missing analysts' consensus estimates of $0.47 by $0.11. The biotechnology company had revenue of $664.46 million for the quarter.

The following companies are subsidiaries of Novozymes A/S: PrecisionBiotics Group Limited, OrganoBalance GmbH, Pacific Vet Group-USA, Allopartis, TJ Technologies, Iogen Bio-Products, Natural Industries, and more.

Shares of NVZMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
1/31/2024
Today
4/04/2025
Record date for 4/23 Dividend
4/07/2025
Ex-Dividend for 4/23 Dividend
4/07/2025
Dividend Payable
4/23/2025
Next Earnings (Estimated)
5/01/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
OTCMKTS:NVZMY
Employees
6,756
Year Founded
2000

Profitability

Trailing P/E Ratio
38.71
Forward P/E Ratio
33.60
P/E Growth
3.87
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$2.60 billion
Cash Flow
$0.84 per share
Price / Cash Flow
72.83
Book Value
$4.45 per share
Price / Book
13.74

Miscellaneous

Free Float
N/A
Market Cap
$28.64 billion
Optionable
Not Optionable
Beta
0.91

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?

Get This Free Report

This page (OTCMKTS:NVZMY) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners